Epigenomics hopes to obtain $6.6 million in a funding round it plans to launch next month. The company is the maker of the Epi proColon test, a blood-based assay for screening colorectal cancer. Proceeds from the planned fundraising will be used to finance the company's operations as well as expand its capabilities for product distribution.
Cancer molecular Dx firm seeks to obtain $6.6 million
SmartBrief Job Listings for Health Care
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.
|Assistant Vice President - Dental Director||